[HTML][HTML] Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review
A Dey, K Vaishak, D Deka, AK Radhakrishnan, S Paul… - Infection, 2023 - Springer
Purpose The COVID-19 pandemic caused by the novel Severe Acute Respiratory Syndrome
Corona Virus 2 (SARS-CoV-2) has put the world in a medical crisis for the past three years; …
Corona Virus 2 (SARS-CoV-2) has put the world in a medical crisis for the past three years; …
Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19: a …
S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu… - Jama, 2023 - jamanetwork.com
IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor
clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin …
clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin …
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus …
L Tian, T Qiang, X Yang, Y Gao, X Zhai, K Kang… - European Journal of …, 2023 - Elsevier
Although no longer a public health emergency of international concern, COVID-19 remains
a persistent and critical health concern. The development of effective antiviral drugs could …
a persistent and critical health concern. The development of effective antiviral drugs could …
[HTML][HTML] Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial
TT Li, B Zhang, H Fang, M Shi, WQ Yao, Y Li… - …, 2023 - thelancet.com
Background Long-term effects of human mesenchymal stem cell (MSC) treatment on COVID-
19 patients have not been fully characterized. The aim of this study was to evaluate the …
19 patients have not been fully characterized. The aim of this study was to evaluate the …
Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study
G Deng, D Li, Y Sun, L Jin, Q Zhou… - Journal of Medical …, 2023 - Wiley Online Library
Chinese guidelines prioritize the use of Azvudine and nirmatrelvir–ritonavir in COVID‐19
patients. Nevertheless, the real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir …
patients. Nevertheless, the real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir …
[HTML][HTML] Molnupiravir, nirmatrelvir/ritonavir, or sotrovimab for high-risk COVID-19 patients infected by the omicron variant: hospitalization, mortality, and time until …
L Cegolon, R Pol, O Simonetti, F Larese Filon… - Pharmaceuticals, 2023 - mdpi.com
Background. Several drugs which are easy to administer in outpatient settings have been
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …
[HTML][HTML] Safety and efficacy of Paxlovid against Omicron variants of coronavirus disease 2019 in elderly patients
C Weng, R Xie, G Han, Y Yuan, S Li, C Wang… - Infectious Diseases and …, 2023 - Springer
Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective
therapeutic interventions are urgently required. We clarified the safety and efficacy of …
therapeutic interventions are urgently required. We clarified the safety and efficacy of …
Amplification-Free Ratiometric Electrochemical Aptasensor for Point-of-Care Detection of Therapeutic Monoclonal Antibodies
J Wan, Y Liang, Q Hu, Z Liang, W Feng, Y Tian… - Analytical …, 2023 - ACS Publications
The rapid quantification of therapeutic monoclonal antibodies (mAbs) is of great significance
to their pharmacokinetics/pharmacodynamics (PK/PD) research and the personalized …
to their pharmacokinetics/pharmacodynamics (PK/PD) research and the personalized …
In vitro and in vivo suppression of SARS‐CoV‐2 replication by a modified, short, cell‐penetrating peptide targeting the C‐terminal domain of the viral spike protein
Peptides are promising therapeutic agents for COVID‐19 because of their specificity, easy
synthesis, and ability to be fine‐tuned. We previously demonstrated that a cell‐permeable …
synthesis, and ability to be fine‐tuned. We previously demonstrated that a cell‐permeable …
Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study
M Shen, C Xiao, Y Sun, D Li, P Wu, L Jin, Q Wu, Y Dian… - MedRxiv, 2023 - medrxiv.org
Current guidelines prioritize the use of the Azvudine in coronavirus disease 2019 (COVID-
19) patients. However, the clinical effectiveness of Azvudine in real-world studies was …
19) patients. However, the clinical effectiveness of Azvudine in real-world studies was …